Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Subscribe To Our Newsletter & Stay Updated
